ReviewBrain, behavior, & immunity - health2026
Exploring the role of neuro-immune modulation for psoriasis management: a narrative review of existing evidence and future therapies.
Review in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis is a chronic immune-mediated skin disease associated with substantial disease burden and comorbidities including cardiovascular disease, metabolic syndrome, and psychiatric illness. While biologics and small-molecule inhibitors have improved outcomes, disease heterogeneity and the complex drivers of inflammation continue to motivate investigation of complementary therapeutic approaches. Major findings: Recent work highlights the role of neuro-immune dysregulation in psoriasis. Stress-induced dysregulation of the hypothalamic-pituitary-adrenal axis and increased sympathetic activity have been shown to amplify cytokine production and impair immune regulation. Peripherally, sensory neurons release substance P and CGRP, promoting dendritic cell activation and sustaining Th17-driven inflammation. In contrast, the cholinergic anti-inflammatory reflex, mediated by vagus and splenic nerves through α7 nicotinic acetylcholine receptor signaling, provides an endogenous mechanism to suppress inflammation. Preclinical studies demonstrate that denervation, neuropeptide receptor blockade, vagus nerve stimulation (VNS), and focused ultrasound (fUS) of the splenic nerve attenuate inflammatory immune cell activation and reduce pro-inflammatory cytokine production. Early clinical studies suggest that non-invasive VNS and splenic fUS are safe, feasible, and may reduce systemic inflammatory activity. Additional emerging strategies include neuropeptide receptor blockade, phototherapy-mediated neuroimmune modulation, and lifestyle interventions targeting stress and systemic inflammation. Conclusion: Psoriasis arises from complex interactions among immune, cutaneous, and neural systems. Growing evidence suggests that neuroimmune pathways may represent therapeutic targets beyond conventional cytokine-directed approaches. While preclinical studies and early clinical investigations support the feasibility of neuromodulatory strategies such as vagus nerve stimulation and splenic focused ultrasound, their efficacy in psoriasis remains to be established. Further mechanistic studies and well-designed clinical trials are needed to define their therapeutic role, optimize treatment parameters, and determine long-term safety and clinical effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.